Policy & Regulation
BioArctic to Provide Financial Support for Post-doc Research at Uppsala University
16 May 2018 - - Stockholm, Sweden-based research based biopharma company BioArctic AB (NASDAQ Stockholm: BIOA B) has signed an extended research collaboration agreement with Uppsala University, Department of Pharmaceutical Biosciences, the company said.
The extended research collaboration concerns technologies for increased passage across the blood-brain barrier and BioArctic will contribute financial support for a three year post-doc research position.
The new extended research collaboration aims to develop innovative technologies to increase the passage of antibodies also into nerve cells.
This can be of great value for the diagnosis and treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
BioArctic AB is focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
The company is also developing a potential treatment for complete spinal cord injury.


Related Headlines